| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
17α,20β-Dihydroxy-4-pregnen-3-one targets steroid hormone receptors, particularly progesterone receptors. As a progestogen, it binds to progesterone receptors and activates downstream signaling pathways involved in reproduction. The compound also serves as a precursor for the synthesis of other steroid hormones, including androgens and estrogens. In fish, it is the major maturation-inducing steroid (MIS) that triggers oocyte maturation and ovulation. Its targets include nuclear receptors and membrane-associated receptors involved in steroid hormone signaling.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 17α,20β-Dihydroxy-4-pregnen-3-one acts as a progestogen, binding to progesterone receptors and activating downstream signaling pathways. In fish ovarian follicles, the compound induces oocyte maturation through binding to specific receptors. Its effects on gene expression and cellular signaling have been characterized in various in vitro systems. The compound's role as a precursor for other steroid hormones has been documented. These in vitro findings support its applications in reproductive endocrinology research.
|
| ln Vivo |
In vivo studies have demonstrated that 17α,20β-Dihydroxy-4-pregnen-3-one is a major maturation-inducing steroid in fish, triggering oocyte maturation and ovulation. The compound plays a critical role in the regulation of reproduction in vertebrates. Its levels fluctuate during the reproductive cycle and are regulated by gonadotropins. The compound's effects on reproductive function have been studied in various animal models. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties and to understand its role in human reproduction.
|
| Enzyme Assay |
In vitro receptor binding assays for 17α,20β-Dihydroxy-4-pregnen-3-one typically involve testing its binding affinity to progesterone receptors and other steroid hormone receptors. Binding affinity is measured using radioligand binding assays or fluorescence polarization assays. Receptor activation is assessed using reporter gene assays measuring transcriptional activity. For fish studies, binding to the maturation-inducing steroid receptor is assessed using membrane binding assays. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for 17α,20β-Dihydroxy-4-pregnen-3-one involve culturing cells expressing steroid hormone receptors to evaluate its effects. Cells are treated with varying concentrations of the compound and receptor activation is measured using reporter gene assays. For fish ovarian follicle studies, follicles are treated with the compound and oocyte maturation is assessed. Cell viability is assessed using standard assays. Gene expression changes are measured by quantitative PCR. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for 17α,20β-Dihydroxy-4-pregnen-3-one utilize fish models to study its role in reproduction. Fish are treated with the compound and oocyte maturation and ovulation are monitored. Hormone levels are measured in blood and tissue samples. For reproductive toxicology studies, animals are exposed to endocrine-disrupting compounds and the effects on 17α,20β-DHP levels and reproductive function are assessed. Parameters assessed include spawning success, fecundity, and developmental abnormalities. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 17α,20β-Dihydroxy-4-pregnen-3-one reflect its nature as a steroid hormone. It has a molecular weight consistent with its structure. As a lipophilic steroid, it is transported in the blood bound to carrier proteins and distributed to target tissues. The compound is metabolized through standard steroid hormone pathways in the liver. Its half-life is determined by its metabolism and clearance. Complete pharmacokinetic profiling including half-life, clearance, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 17α,20β-Dihydroxy-4-pregnen-3-one has been evaluated in the context of its use as a research chemical. As a steroid hormone, it may have endocrine effects that should be carefully evaluated. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile. The compound's hormonal activity suggests it should be handled with caution.
|
| References |
[1]. J V Planas, et al. Maturation-associated changes in the response of the salmon testis to the steroidogenic actions of gonadotropins (GTH I and GTH II) in vitro. Biol Reprod. 1995 Mar;52(3):697-704.
|
| Additional Infomation |
(20R)-17,20-dihydroxypregn-4-en-3-one is a 17,20-dihydroxypregn-4-en-3-one.
17α,20β-Dihydroxy-4-pregnen-3-one (CAS# 1662-06-2) is a steroid hormone, also known as 17,20β-DHP. It is a metabolite of progesterone and a precursor to other steroid hormones. The compound is involved in the regulation of reproductive function and is a major progestogen in fish and other vertebrates. In fish, it is the major maturation-inducing steroid that triggers oocyte maturation and ovulation. 17α,20β-Dihydroxy-4-pregnen-3-one is used in research applications for studying steroid hormone biology, reproduction, and endocrine disruption. It is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C21H32O3
|
|---|---|
| Molecular Weight |
332.48
|
| Exact Mass |
332.235
|
| CAS # |
1662-06-2
|
| PubChem CID |
107701
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
487.1±45.0 °C at 760 mmHg
|
| Melting Point |
201-202ºC
|
| Flash Point |
262.5±25.2 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.568
|
| LogP |
2.88
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
24
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H]([C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C)O)O
|
| InChi Key |
MASCESDECGBIBB-FSHQYNQFSA-N
|
| InChi Code |
InChI=1S/C21H32O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12-13,16-18,22,24H,4-11H2,1-3H3/t13-,16-,17+,18+,19+,20+,21+/m1/s1
|
| Chemical Name |
(8R,9S,10R,13S,14S,17R)-17-hydroxy-17-[(1R)-1-hydroxyethyl]-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (300.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0077 mL | 15.0385 mL | 30.0770 mL | |
| 5 mM | 0.6015 mL | 3.0077 mL | 6.0154 mL | |
| 10 mM | 0.3008 mL | 1.5038 mL | 3.0077 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
